Ethyl eicosapentaenoic acid - Amarin

Drug Profile

Ethyl eicosapentaenoic acid - Amarin

Alternative Names: AMR-101; Eicosapentaenoic acid ethyl ester - Amarin; Eicosapentanoic acid ethyl ester; Ethyl eicosapentaenoate; Ethyl eicosopentaenoate; Ethyl icopenate; Ethyl-EPA; Icosapent ethyl; Icosapentaenoic acid ethyl ester; LAX-101; LAX-101c; Miraxion™; Pure EPA; Ultra-pure eicosapentaenoic acid; Ultra-pure EPA; Ultra-pure ethyl ecosapentaenoic acid; Ultra-pure ethyl EPA; Vascepa

Latest Information Update: 27 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Scarista
  • Developer Amarin Corporation; Biologix FZCo; Eddingpharm
  • Class Antidepressants; Antihyperlipidaemics; Antiplatelets; Eicosanoids; Esters; Omega 3 fatty acids; Small molecules
  • Mechanism of Action Phospholipase A2 inhibitors; Platelet aggregation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Huntington's disease
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Hypertriglyceridaemia
  • Discontinued Huntington's disease; Major depressive disorder; Memory disorders; Parkinson's disease; Psychotic disorders

Most Recent Events

  • 26 Jul 2018 Registered for Hypertriglyceridaemia in United Arab Emirates (PO)
  • 24 May 2018 Amarin announces patent litigation settlement agreement with Teva related to Teva’s ANDA for generic forms of Vascepa (icosapent ethyl) capsules in USA
  • 21 Mar 2018 Registered for Hypertriglyceridaemia in Lebanon (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top